MedTrace Logo

An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance

NCT00329095 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-05-24

No results posted yet for this study

Summary

This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.

Conditions

Interventions

DRUG

travoprost, latanoprost, or bimatoprost

DRUG

Additional ocular hypotensive medication

Sponsors & Collaborators

  • Robin, Alan L., M.D.

    lead INDIV

Principal Investigators

  • Alan L. Robin, MD · Alan L. Robin, M.D.

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2006-04-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329095 on ClinicalTrials.gov